List PLR Content Marketing Belize: Byetta

Byetta is a brand name of exenatide, approved by the FDA in the following formulation(s):

BYETTA (exenatide synthetic - injectable; subcutaneous)

Manufacturer: AMYLIN

Approval date: April 28, 2005

Strength(s): 300MCG/1.2ML (250MCG/ML) ^[RLD], 600MCG/2.4ML (250MCG/ML) ^[RLD]

Has a generic version of Byetta been approved?

No. There is currently no therapeutically equivalent version of Byetta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byetta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Patent 5,424,286
Issued: June 13, 1995
Inventor(s): Eng; John
This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
Patent expiration dates:
- December 1, 2016
  ✓
  Patent use: STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
- December 1, 2016
  ✓
  Patent use: TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

Methods for regulating gastrointestinal motility
Patent 6,858,576
Issued: February 22, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava & Beeley; Nigel Robert Arnold & Prickett; Kathryn S.
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Patent expiration dates:
- January 6, 2017
  ✓
  Patent use: REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

Methods for glucagon suppression
Patent 6,872,700
Issued: March 29, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
Patent expiration dates:
- January 14, 2020
  ✓
  Patent use: LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4

Exendin agonist formulations and methods of administration thereof
Patent 6,902,744
Issued: June 7, 2005
Inventor(s): Kolterman; Orville G. & Young; Andrew A.
Assignee(s): Amylin Pharmaceuticals, Inc.
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Patent expiration dates:
- January 14, 2020
  ✓
  Drug product

Use of exendins for the reduction of food intake
Patent 6,956,026
Issued: October 18, 2005
Inventor(s): Beeley; Nigel Robert Arnold & Bhavsar; Sunil
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- January 7, 2018
  ✓
  Patent use: REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

Pharmaceutical compositions containing exendins
Patent 7,297,761
Issued: November 20, 2007
Inventor(s): Beeley; Nigel Robert Arnold & Prickett; Kathryn S. & Bhavsar; Sunil & Young; Andrew & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- October 15, 2017
  ✓
  Drug product

Exendin pharmaceutical compositions
Patent 7,521,423
Issued: April 21, 2009
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Patent expiration dates:
- October 15, 2017
  ✓
  Drug product

Exendins and exendin agonists for weight reduction and obesity
Patent 7,741,269
Issued: June 22, 2010
Inventor(s): Young; Andrew A. & Bhavsar; Sunil & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- January 7, 2018
  ✓
  Patent use: USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

List PLR Content Marketing Belize

Thursday, October 27, 2016

Byetta

BYETTA (exenatide synthetic - injectable; subcutaneous)

Has a generic version of Byetta been approved?

Related Patents

See also...

No comments:

Post a Comment